Canndoc
Manufacturing · Israel · 201-500 Employees
View Company Info for Free
Overview
Headquarters
85 Medinat ha-Yehudim Herzliya St, Tel A...Phone Number
+972 774605012Website
www.intercure.coRevenue
$68.3 MillionStock Symbol
INCRIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Canndoc
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Explore more
Canndoc Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Canndoc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Canndoc had a recent Job posting/layoffs
Earning: See what the market has to say on Canndoc recently announced quarterly report
Check if Canndoc has recently received funding, and reach out quickly before it becomes old news!
Canndoc, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Canndoc launches new products
Funding: Get notified immidiatlly once Canndoc has new funding data
Congratulate Masked Content for being promoted to Masked Content at Canndoc
Check out if Canndoc is spiking on competitors!
Recommended Actions
Find VP level buyers at Canndoc
Find 3 more new buyers
Company Profile Activity
Activity Insights
Canndoc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Canndoc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Canndoc.
Canndoc financials insights
Gather financial insights about Canndoc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$18M
Canndoc Tech Stack
A closer look at the technologies used by Canndoc
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Executive Move
Executive Moves, Board of Directors
Canndoc News & Media
InterCure Secures NIS 22 Million in Private Placement - GlobeNewswire
●The funding includes investments commitments from key shareholders of the Company, including the Company’s CEO Alexander Rabinovich, as well as leading...InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), today announced that, further to the Company’s prior reports regarding growing demand in Germany and opportunities arising from the recent U.S. federal rescheduling of cannabis, the Company has entered into a binding term sheet providing for funding commitments of NIS 22 million (approximately US$7.4 million), which may increase to NIS 54 millionInterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets.InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Canndoc
Sign Up For FreeTo access detailed company insights
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed... Read More
